vs
Esperion Therapeutics, Inc.（ESPR）与Turning Point Brands, Inc.（TPB）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Turning Point Brands, Inc.的1.4倍（$168.4M vs $121.0M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 29.2%），过去两年Turning Point Brands, Inc.的营收复合增速更高（20.7% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Turning Point Australia（TPAUS）是一家位于澳大利亚的保守派游说团体，隶属于美国转折点组织但保持独立运营，由乔尔·贾马尔创立并于2023年完成注册。该团体目前正积极行动，试图影响2026年3月举行的南澳大利亚州选举结果。
ESPR vs TPB — 直观对比
营收规模更大
ESPR
是对方的1.4倍
$121.0M
营收增速更快
ESPR
高出114.5%
29.2%
两年增速更快
TPB
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $121.0M |
| 净利润 | — | $8.2M |
| 毛利率 | — | 55.9% |
| 营业利润率 | 50.6% | 16.5% |
| 净利率 | — | 6.8% |
| 营收同比 | 143.7% | 29.2% |
| 净利润同比 | — | 239.8% |
| 每股收益（稀释后） | $0.32 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRTPB
| Q4 25 | $168.4M | $121.0M | ||
| Q3 25 | $87.3M | $119.0M | ||
| Q2 25 | $82.4M | $116.6M | ||
| Q1 25 | $65.0M | $106.4M | ||
| Q4 24 | $69.1M | $93.7M | ||
| Q3 24 | $51.6M | $90.7M | ||
| Q2 24 | $73.8M | $93.2M | ||
| Q1 24 | $137.7M | $83.1M |
净利润ESPRTPB
| Q4 25 | — | $8.2M | ||
| Q3 25 | $-31.3M | $21.1M | ||
| Q2 25 | $-12.7M | $14.5M | ||
| Q1 25 | $-40.5M | $14.4M | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | $-29.5M | $12.4M | ||
| Q2 24 | $-61.9M | $13.0M | ||
| Q1 24 | $61.0M | $12.0M |
毛利率ESPRTPB
| Q4 25 | — | 55.9% | ||
| Q3 25 | — | 59.2% | ||
| Q2 25 | — | 57.1% | ||
| Q1 25 | — | 56.0% | ||
| Q4 24 | — | 56.0% | ||
| Q3 24 | — | 55.6% | ||
| Q2 24 | — | 54.1% | ||
| Q1 24 | — | 58.2% |
营业利润率ESPRTPB
| Q4 25 | 50.6% | 16.5% | ||
| Q3 25 | -11.4% | 21.8% | ||
| Q2 25 | 8.6% | 22.6% | ||
| Q1 25 | -34.0% | 21.8% | ||
| Q4 24 | -6.4% | 19.1% | ||
| Q3 24 | -31.0% | 22.9% | ||
| Q2 24 | 3.5% | 24.5% | ||
| Q1 24 | 52.5% | 23.2% |
净利率ESPRTPB
| Q4 25 | — | 6.8% | ||
| Q3 25 | -35.9% | 17.7% | ||
| Q2 25 | -15.4% | 12.4% | ||
| Q1 25 | -62.2% | 13.5% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | -57.2% | 13.6% | ||
| Q2 24 | -83.9% | 14.0% | ||
| Q1 24 | 44.3% | 14.5% |
每股收益（稀释后）ESPRTPB
| Q4 25 | $0.32 | $0.40 | ||
| Q3 25 | $-0.16 | $1.13 | ||
| Q2 25 | $-0.06 | $0.79 | ||
| Q1 25 | $-0.21 | $0.79 | ||
| Q4 24 | $-0.14 | $0.15 | ||
| Q3 24 | $-0.15 | $0.68 | ||
| Q2 24 | $-0.33 | $0.68 | ||
| Q1 24 | $0.34 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $222.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $372.0M |
| 总资产 | $465.9M | $763.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRTPB
| Q4 25 | $167.9M | $222.8M | ||
| Q3 25 | $92.4M | $201.2M | ||
| Q2 25 | $86.1M | $109.9M | ||
| Q1 25 | $114.6M | $99.6M | ||
| Q4 24 | $144.8M | $48.9M | ||
| Q3 24 | $144.7M | $33.6M | ||
| Q2 24 | $189.3M | $142.2M | ||
| Q1 24 | $226.6M | $130.9M |
股东权益ESPRTPB
| Q4 25 | $-302.0M | $372.0M | ||
| Q3 25 | $-451.4M | $358.2M | ||
| Q2 25 | $-433.5M | $224.8M | ||
| Q1 25 | $-426.2M | $203.4M | ||
| Q4 24 | $-388.7M | $190.4M | ||
| Q3 24 | $-370.2M | $185.7M | ||
| Q2 24 | $-344.2M | $172.8M | ||
| Q1 24 | $-294.3M | $160.0M |
总资产ESPRTPB
| Q4 25 | $465.9M | $763.8M | ||
| Q3 25 | $364.0M | $742.8M | ||
| Q2 25 | $347.1M | $595.8M | ||
| Q1 25 | $324.0M | $564.6M | ||
| Q4 24 | $343.8M | $493.4M | ||
| Q3 24 | $314.1M | $488.0M | ||
| Q2 24 | $352.3M | $591.6M | ||
| Q1 24 | $373.1M | $586.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $24.9M |
| 自由现金流经营现金流 - 资本支出 | — | $21.5M |
| 自由现金流率自由现金流/营收 | — | 17.8% |
| 资本支出强度资本支出/营收 | 0.0% | 2.8% |
| 现金转化率经营现金流/净利润 | — | 3.03× |
| 过去12个月自由现金流最近4个季度 | — | $43.8M |
8季度趋势，按日历期对齐
经营现金流ESPRTPB
| Q4 25 | $45.2M | $24.9M | ||
| Q3 25 | $-4.3M | $3.3M | ||
| Q2 25 | $-31.4M | $11.8M | ||
| Q1 25 | $-22.6M | $17.4M | ||
| Q4 24 | $-35.0M | $17.7M | ||
| Q3 24 | $-35.3M | $13.2M | ||
| Q2 24 | $-7.2M | $13.4M | ||
| Q1 24 | $53.8M | $22.6M |
自由现金流ESPRTPB
| Q4 25 | — | $21.5M | ||
| Q3 25 | — | $-721.0K | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $15.2M | ||
| Q4 24 | — | $16.6M | ||
| Q3 24 | $-35.5M | $12.6M | ||
| Q2 24 | $-7.3M | $10.9M | ||
| Q1 24 | $53.8M | $22.3M |
自由现金流率ESPRTPB
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -0.6% | ||
| Q2 25 | — | 6.7% | ||
| Q1 25 | — | 14.3% | ||
| Q4 24 | — | 17.8% | ||
| Q3 24 | -68.7% | 13.9% | ||
| Q2 24 | -9.9% | 11.7% | ||
| Q1 24 | 39.0% | 26.8% |
资本支出强度ESPRTPB
| Q4 25 | 0.0% | 2.8% | ||
| Q3 25 | 0.0% | 3.4% | ||
| Q2 25 | 0.0% | 3.4% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.0% | 1.2% | ||
| Q3 24 | 0.3% | 0.7% | ||
| Q2 24 | 0.1% | 2.7% | ||
| Q1 24 | 0.1% | 0.4% |
现金转化率ESPRTPB
| Q4 25 | — | 3.03× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 7.34× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | 0.88× | 1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TPB
| US | $111.5M | 92% |
| Non Us | $9.6M | 8% |
